Experimental study of the effect of the active substance of miramistin® on the infectious activity of SARS-CoV-2 in vitro


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate and laboratorily confirm the effect of miramistin9 (benzyldimethyl-myristoylamine-propylammonium (BMPA)) on the infectious activity of SARS-CoV-2 in vitro. Materials and methods. The investigators used cultured Vero CCL-81 cells derived from the monkey kidney and the laboratory SARS-CoV-2 strain Dubrovka. They applied cultural, virological, molecular biological, and statistical studies. All experiments used the original pharmaceutical substance BMPA chloride (OOO «INFAMED», Russia). Results. The study of BMPA cytotoxicity in the cultured cells indicated that its CTD50 was 0,0091±0,002%, and the MTC was 0.005%. The original drug had a pronounced virucidal activity against SARS-CoV-2, by completely suppressing its infectivity at a concentration of0.005% or higher. An additional experiment identifying the result by virus titration and in the virus-specific real-time RT-PCR assay confirmed complete virus inactivation in the range of non-toxic concentrations of0.01-0.0025%. Conclusion. The original pharmaceutical substance BMPA chloride in vitro exhibits a pronounced virucidal activity at the concentrations corresponding to that of the active substance in miramistin (0.01%), and even at lower concentrations (0.005 and 0.0025%).

Full Text

Restricted Access

About the authors

Irina A. Leneva

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: wnyfd385@yandex.ru
BiolD, Head, Laboratory of Experimental Virology

Anastasia V. Gracheva

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: 95@mail.ru
Junior Researcher, Laboratory of Molecular Virology

Ekaterina R. Korchevaya

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: c.korchevaya@gmail.com
Junior Researcher, Laboratory of Molecular Virology

Daria I. Smirnova

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: daria.sm.1995@mail.ru
Junior Researcher, Laboratory of Molecular Virology

Evgeny B. Faizuloev

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: faizuloev@mail.ru
Cand. Biol. Sci., Head, Laboratory of Molecular Virology

References

  1. ICTV (International Committee on Taxonomy of Viruses). https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/222/coronaviridae
  2. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J. et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 2020; 7(1): 11. doi: 10.1186/s40779-020-00240-0.
  3. Khan F.A. The role of Selectivity of the SARS-CoV-2 Virus for Human Genetic Profiles in Susceptibility and Resistance to COVID-19. New Microbes New Infect. 2020; 36: 100697. https://doi.org/10.1016/j.nmni.2020.100697
  4. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473-5. doi: 10.1016/S0140-6736(20)30317-2.
  5. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8(5): 475-81. doi: 10.1016/S2213-2600(20)30079-5
  6. Liu K., Fang Y.Y., Deng Y., Liu W., Wang M.F., Ma J.P. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl.). 2020; 133(9): 1025-31. doi: 10.1097/CM9.0000000000000744
  7. Oran D.P., Topol E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Annals of internal medicine 2020; 173(5), 362-7. doi: 10.7326/M20-3012
  8. Abduljalil J.M., Abduljalil B.M. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New Microbes New Infect. 2020; 35: 100672. doi: 10.1016/j. nmni.2020.100672
  9. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239 -42. doi: 10.1001/jama.2020.264832091533.
  10. Harrison S.L., Fazio-Eynullayeva E., Lane D.A., Underhill P. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020; 17(9): e1003321. doi: 10.1371/journal.pmed.1003321
  11. Liu Y., Sun W., Li J., Chen L., Wang Y., Zhang L., Yu L. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv 2020. https://doi.org/10.1101/2020.02.17.20024166
  12. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; 323(18): 1824-36. doi: 10.1001/jama.2020.6019
  13. Дунаевский А.М., Кириченко И.М. Местная терапия инфекционно-воспалительных заболеваний респираторной системы. Лечащий врач 2014; (10): 1-3. www.lvrach.ru
  14. Шабалдина Е.В., Рязанцев С.В., Шабалдин А.В. Эффективность применения мирамистина у детей раннего и дошкольного возраста с гипертрофией миндалин лимфоидного глоточного кольца, с рецидивирующими острыми респираторными инфекциями и сенсибилизацией к Streptococcus pyogenes. Педиатрия. Журнал им. Г.Н. Сперанского 2015; 94(6): 96-104
  15. Николаева И.В., Герасимова Е.С., Павлова Т.Ю. Эффективность мирамистина в коррекции нарушений микробиоценоза ротоглотки у часто болеющих детей. Российский педиатрический журнал 2016; 19(1): 9-14. doi: 10.18821/15609561-2016-19 (1)-9-14
  16. Зырянов С.К., Байбулатова Е.А. Клинико-фармакологический анализ применения антисептических препаратов в практической медицине. Вопросы практической педиатрии 2021; 16(6): 77-92. doi: 10.20953/1817-7646-2021-6-77-92
  17. Винцерская Г.А., Притуло О.А., Шеренговская Ю.В., Бабанин В.А., Мараках Марван Якин Нажи. Мирамистин: от дерматовенерологии до профилактики коронавирусной инфекции. Обзор литературы. Российский журнал кожных и венерических болезней 2020; 23(5): 341-6. DOI: https://doi.org/10.17816/dv59976
  18. Грачева А.В., Корчевая Е.Р., Кудряшова А.М., Борисова О.В., Петруша О.А., Смирнова Д.И. и др. Адаптация МТТ-теста для определения нейтрализующих антител к вирусу SARS-CoV-2. Журнал микробиологии, эпидемиологии и иммунобиологии 2021; 98(3): 253-65. https://doi.org/10.36233/0372-9311-136
  19. Ramakrishnan M.A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016; 5(2): 85-6. https://doi.org/10.5501/wjv.v5.i2.85
  20. Gracheva A.V., Korchevaya E.R., Ammour Y.I., Smirnova D.I., Sokolova O.S., Glukhov G.S. et al. Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light. Arch. Virol. 2022: 1-11. doi: 10.1007/s00705-022-05530-7
  21. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 16 (18.08.2022). https://edu-rosminzdrav.ru.com/profilaktika-diagnostika-i-lechenie-covid-19/?ysclid=l99yqp3rvz289472438
  22. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020; 71(9): 2459-68. doi: 10.1093/cid/ciaa530

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies